IL17A and lung cancer: These findings suggest that IL-17A derived from lung cancer cells promotes osteoclastogenesis by inhibiting apoptosis of osteoclast precursors and that IL-17A could be a potential therapeutic target for cancer-associated bone resorption in lung cancer patients [121].